<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03308799</url>
  </required_header>
  <id_info>
    <org_study_id>MC2-01-C2</org_study_id>
    <nct_id>NCT03308799</nct_id>
  </id_info>
  <brief_title>A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream</brief_title>
  <official_title>A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to Vehicle and Active Comparator in Subjects With Mild-to-Moderate Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MC2 Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MC2 Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a randomized, investigator-blind, multicentre, vehicle- and
      comparator-controlled, parallel-group trial with the purpose of evaluating efficacy, safety
      and convenience of the MC2-01 cream.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The MC2-01 Cream is designed for optimal patient satisfaction - it quickly absorbs into the
      skin leaving it nicely moisturized allowing patients to move on in daily routines. In this
      trial, the MC2-01 cream will be compared to a marketed product CAL/BDP combination and
      vehicle. The purpose of the trial is to compare the clinical efficacy, safety, and
      convenience of this cream to the marketed product. The trial will include a 8-week treatment
      period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 3, 2017</start_date>
  <completion_date type="Actual">June 8, 2018</completion_date>
  <primary_completion_date type="Actual">June 8, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Decrease in the Physicians Global Assessment (PGA) Score of Minimum 2 Points on a Scale From 0-4 From Baseline to Week 8</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>Psoriasis treatment success rate is measured at week 8 by the use of a Physician Global Assessment (PGA) score. Success is defined as a decrease from Baseline of minimum 2 point on a scale from 0 - 4, where: 0 = Clear; 1 = Almost clear; 2 = Mild Plaque thickening; 3 = Moderate Plaque thickening, 4 = Severe Plaque thickening.
The number of participants referred in the data sets are the number of participants, who achieved a successful treatment success.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in mPASI Score</measure>
    <time_frame>Baseline and 8 weeks</time_frame>
    <description>The extent and severity of the participant's psoriasis is assessed using a modified PASI scoring system (minus scalp, face, and flexures) at each 3 areas (arms, trunk and legs) using a scale from 0 - 6, where 0 = no psoriasis involvement and 6 = 90-100% involvement.
The severity is assessed at each 3 areas (arms, trunk and legs) for each of the sign redness, thickness and scaliness using a scale from 0 - 4, where 0 represents none and 4 represents very severe.
The mPASI score is calculated from the individual scores by use of the following equation:
Arms 0.2 (Redness + Thickness + Scaliness) E = X Trunk 0.3 (Redness + Thickness + Scaliness) E = Y Legs 0.4 (Redness + Thickness + Scaliness) E = Z
The sum of X + Y + Z = m-PASI score resulting in a minimum score of 0 and a maximum score (worst possible) of 64.8.
The percent change in mPASI score is defined as the Baseline minus the Week 8 divided by Baseline score multiplied by 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Treatment Convenience Scale</measure>
    <time_frame>8 weeks</time_frame>
    <description>Subject assessment of treatment convenience using a Psoriasis Treatment Convenience Scale is defined as a sum of questions 1-5, where each question is scored on a scale from 1-10.
How easy was the treatment to apply to the skin? &quot;Very difficult&quot; is 1 and &quot;Very easy&quot; is 10 How greasy was the treatment when applying it to the skin? &quot;Very greasy&quot; is 1 and &quot;Not greasy&quot; is 10 How moisturised did your skin feel after applying the treatment? &quot;Not moisturized&quot; is 1 and &quot;Very moisturized&quot; is 10 How greasy did your skin feel after applying the treatment? &quot;Very greasy&quot; is 1 and &quot;Not greasy&quot; is 10 How much did treating your skin disrupt your daily routine? &quot;Very disturbing&quot; is 1 and &quot;Not disturbing&quot; is 10</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">794</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>MC2-01 Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cal/BDP combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcipotriene/betamethasone (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cream vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One application daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MC2-01 cream</intervention_name>
    <description>MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream</description>
    <arm_group_label>MC2-01 Cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cal/BDP combination</intervention_name>
    <description>calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%</description>
    <arm_group_label>Cal/BDP combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cream vehicle</intervention_name>
    <description>Vehicle Cream</description>
    <arm_group_label>Cream vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provided written informed consent

          -  Generally healthy males or non-pregnant females, of any race or ethnicity, who are at
             least 18 years of age at the time of screening

          -  Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6
             months duration that involves the trunk and/or limbs that is amenable to topical
             treatment with a maximum of 100 g of trial medication per week

          -  Have a PGA of disease severity of mild or moderate on the body (trunk and/or limbs)

          -  An mPASI score of at least 2

          -  Have a treatment area involving 2- 30% of the body surface area (BSA)

        Exclusion Criteria:

          -  Current diagnosis of unstable forms of psoriasis

          -  Other inflammatory skin disease in the treatment area that may confound the evaluation
             of the psoriasis vulgaris

          -  Presence of pigmentation, extensive scarring, pigmented lesions or sunburn in the
             treatment areas

          -  Planned exposure to either natural or artificial sunlight

          -  History of hypersensitivity to any component of the test product or reference product

          -  Current or past history of hypercalcemia, vitamin D toxicity, severe renal
             insufficiency, or severe hepatic disorders

          -  Systemic treatment with biological therapies

          -  Use of systemic treatments that suppress the immune system and other systemic
             chemotherapeutic antineoplastic therapy within 4 weeks prior to the baseline visit and
             during the trial

          -  Use of phototherapy within 4 weeks prior to Visit 1/Baseline and during the trial;

          -  Use of topical treatments, except for emollients and non-medicated shampoos, with a
             possible effect on psoriasis within 2 weeks prior to Visit 1/Baseline

          -  Clinical signs of skin infection with bacteria, viruses, or fungi

          -  Known Human Immunodeficiency Virus (HIV) infection

          -  Any chronic or acute medical condition that may pose a risk to the safety of the
             subject, or may interfere with the assessment of safety or efficacy in this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda S. Gold, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard Herdener, MD</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 9, 2017</study_first_submitted>
  <study_first_submitted_qc>October 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <results_first_submitted>July 11, 2019</results_first_submitted>
  <results_first_submitted_qc>October 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2019</results_first_posted>
  <last_update_submitted>October 7, 2019</last_update_submitted>
  <last_update_submitted_qc>October 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03308799/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/99/NCT03308799/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First Subject First Visit: 03-Oct-2017. Last Subject Last Visit: 08-Jun-2018.</recruitment_details>
      <pre_assignment_details>Prior to randomization, the subject entered a washout period (if required) where anti-psoriatic treatment and other relevant medication/treatments were discontinued as defined by the exclusion criteria. The washout/screening period could last for up to 30 days, depending on which disallowed treatments the subject received.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MC2-01 Cream</title>
          <description>MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
MC2-01 cream: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream</description>
        </group>
        <group group_id="P2">
          <title>CAL/BDP Combination</title>
          <description>CAL/BDP (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
CAL/BDP combination: calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%</description>
        </group>
        <group group_id="P3">
          <title>Vehicle</title>
          <description>One application daily for 8 weeks.
Vehicle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="342"/>
                <participants group_id="P2" count="337"/>
                <participants group_id="P3" count="115"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="320"/>
                <participants group_id="P2" count="309"/>
                <participants group_id="P3" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MC2-01 Cream</title>
          <description>MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
MC2-01 cream: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream</description>
        </group>
        <group group_id="B2">
          <title>CAL/BDP Combination</title>
          <description>CAL/BDP (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
CAL/BDP combination: calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%</description>
        </group>
        <group group_id="B3">
          <title>Vehicle</title>
          <description>One application daily for 8 weeks.
Vehicle</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="342"/>
            <count group_id="B2" value="337"/>
            <count group_id="B3" value="115"/>
            <count group_id="B4" value="794"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.0" spread="14.4"/>
                    <measurement group_id="B2" value="52.6" spread="13.7"/>
                    <measurement group_id="B3" value="50.4" spread="14.3"/>
                    <measurement group_id="B4" value="52.0" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="299"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="495"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="290"/>
                    <measurement group_id="B2" value="299"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="691"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mutiple</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="342"/>
                    <measurement group_id="B2" value="337"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline PGA</title>
          <description>Severity of psoriasis at Baseline</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Mild psoriasis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="145"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate psoriasis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                    <measurement group_id="B2" value="280"/>
                    <measurement group_id="B3" value="95"/>
                    <measurement group_id="B4" value="649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline mPASI</title>
          <description>The extent and severity of the participant's psoriasis are assessed using a modified PASI scoring system at each 3 areas (arms, trunk and legs) using a scale from 0 - 6. 0 = no psoriasis involvement and 6 = 90-100% involvement.The severity is assessed at each for each of the sign redness, thickness and scaliness using a scale from 0 - 4. 0 represents none and 4 represents very severe.</description>
          <units>Calculated score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread="3.9"/>
                    <measurement group_id="B2" value="7.7" spread="4.1"/>
                    <measurement group_id="B3" value="7.1" spread="4.1"/>
                    <measurement group_id="B4" value="7.4" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline BSA</title>
          <description>Percentage involvement of psoriasis on the Body Surface Area at Baseline</description>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.3" spread="6.0"/>
                    <measurement group_id="B2" value="8.4" spread="7.0"/>
                    <measurement group_id="B3" value="7.5" spread="6.1"/>
                    <measurement group_id="B4" value="7.8" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type</title>
          <description>Fitzpatrick Skin Type was recorded at baseline using the following classification: I = Pale white skin, blue/hazel eyes, blond/red hair; II = Fair skin, blue eyes; III = Darker white skin; IV = Light brown skin; V = Brown skin; VI = Dark brown or black skin</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="253"/>
                  </measurement_list>
                </category>
                <category>
                  <title>IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="183"/>
                  </measurement_list>
                </category>
                <category>
                  <title>V</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>VI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Decrease in the Physicians Global Assessment (PGA) Score of Minimum 2 Points on a Scale From 0-4 From Baseline to Week 8</title>
        <description>Psoriasis treatment success rate is measured at week 8 by the use of a Physician Global Assessment (PGA) score. Success is defined as a decrease from Baseline of minimum 2 point on a scale from 0 - 4, where: 0 = Clear; 1 = Almost clear; 2 = Mild Plaque thickening; 3 = Moderate Plaque thickening, 4 = Severe Plaque thickening.
The number of participants referred in the data sets are the number of participants, who achieved a successful treatment success.</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>The analysis was based on the PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>MC2-01 Cream</title>
            <description>MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
MC2-01 cream: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream</description>
          </group>
          <group group_id="O2">
            <title>CAL/BDP Combination</title>
            <description>CAL/BDP (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
CAL/BDP combination: calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>One application daily for 8 weeks.
Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease in the Physicians Global Assessment (PGA) Score of Minimum 2 Points on a Scale From 0-4 From Baseline to Week 8</title>
          <description>Psoriasis treatment success rate is measured at week 8 by the use of a Physician Global Assessment (PGA) score. Success is defined as a decrease from Baseline of minimum 2 point on a scale from 0 - 4, where: 0 = Clear; 1 = Almost clear; 2 = Mild Plaque thickening; 3 = Moderate Plaque thickening, 4 = Severe Plaque thickening.
The number of participants referred in the data sets are the number of participants, who achieved a successful treatment success.</description>
          <population>The analysis was based on the PP population.</population>
          <units>Count of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in mPASI Score</title>
        <description>The extent and severity of the participant's psoriasis is assessed using a modified PASI scoring system (minus scalp, face, and flexures) at each 3 areas (arms, trunk and legs) using a scale from 0 - 6, where 0 = no psoriasis involvement and 6 = 90-100% involvement.
The severity is assessed at each 3 areas (arms, trunk and legs) for each of the sign redness, thickness and scaliness using a scale from 0 - 4, where 0 represents none and 4 represents very severe.
The mPASI score is calculated from the individual scores by use of the following equation:
Arms 0.2 (Redness + Thickness + Scaliness) E = X Trunk 0.3 (Redness + Thickness + Scaliness) E = Y Legs 0.4 (Redness + Thickness + Scaliness) E = Z
The sum of X + Y + Z = m-PASI score resulting in a minimum score of 0 and a maximum score (worst possible) of 64.8.
The percent change in mPASI score is defined as the Baseline minus the Week 8 divided by Baseline score multiplied by 100</description>
        <time_frame>Baseline and 8 weeks</time_frame>
        <population>The analysis was based on the PP population.</population>
        <group_list>
          <group group_id="O1">
            <title>MC2-01 Cream</title>
            <description>MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
MC2-01 cream: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream</description>
          </group>
          <group group_id="O2">
            <title>CAL/BDP Combination</title>
            <description>CAL/BDP (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
CAL/BDP combination: calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>One application daily for 8 weeks.
Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in mPASI Score</title>
          <description>The extent and severity of the participant's psoriasis is assessed using a modified PASI scoring system (minus scalp, face, and flexures) at each 3 areas (arms, trunk and legs) using a scale from 0 - 6, where 0 = no psoriasis involvement and 6 = 90-100% involvement.
The severity is assessed at each 3 areas (arms, trunk and legs) for each of the sign redness, thickness and scaliness using a scale from 0 - 4, where 0 represents none and 4 represents very severe.
The mPASI score is calculated from the individual scores by use of the following equation:
Arms 0.2 (Redness + Thickness + Scaliness) E = X Trunk 0.3 (Redness + Thickness + Scaliness) E = Y Legs 0.4 (Redness + Thickness + Scaliness) E = Z
The sum of X + Y + Z = m-PASI score resulting in a minimum score of 0 and a maximum score (worst possible) of 64.8.
The percent change in mPASI score is defined as the Baseline minus the Week 8 divided by Baseline score multiplied by 100</description>
          <population>The analysis was based on the PP population.</population>
          <units>Percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="279"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-64.8" spread="28.7"/>
                    <measurement group_id="O2" value="-52.3" spread="33.3"/>
                    <measurement group_id="O3" value="-25.7" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Psoriasis Treatment Convenience Scale</title>
        <description>Subject assessment of treatment convenience using a Psoriasis Treatment Convenience Scale is defined as a sum of questions 1-5, where each question is scored on a scale from 1-10.
How easy was the treatment to apply to the skin? &quot;Very difficult&quot; is 1 and &quot;Very easy&quot; is 10 How greasy was the treatment when applying it to the skin? &quot;Very greasy&quot; is 1 and &quot;Not greasy&quot; is 10 How moisturised did your skin feel after applying the treatment? &quot;Not moisturized&quot; is 1 and &quot;Very moisturized&quot; is 10 How greasy did your skin feel after applying the treatment? &quot;Very greasy&quot; is 1 and &quot;Not greasy&quot; is 10 How much did treating your skin disrupt your daily routine? &quot;Very disturbing&quot; is 1 and &quot;Not disturbing&quot; is 10</description>
        <time_frame>8 weeks</time_frame>
        <population>The analysis population is defined as those patients from the PP population that have used study medication within 7 days prior to the day of assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>MC2-01 Cream</title>
            <description>MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
MC2-01 cream: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream</description>
          </group>
          <group group_id="O2">
            <title>CAL/BDP Combination</title>
            <description>CAL/BDP (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
CAL/BDP combination: calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%</description>
          </group>
          <group group_id="O3">
            <title>Vehicle</title>
            <description>One application daily for 8 weeks.
Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Psoriasis Treatment Convenience Scale</title>
          <description>Subject assessment of treatment convenience using a Psoriasis Treatment Convenience Scale is defined as a sum of questions 1-5, where each question is scored on a scale from 1-10.
How easy was the treatment to apply to the skin? &quot;Very difficult&quot; is 1 and &quot;Very easy&quot; is 10 How greasy was the treatment when applying it to the skin? &quot;Very greasy&quot; is 1 and &quot;Not greasy&quot; is 10 How moisturised did your skin feel after applying the treatment? &quot;Not moisturized&quot; is 1 and &quot;Very moisturized&quot; is 10 How greasy did your skin feel after applying the treatment? &quot;Very greasy&quot; is 1 and &quot;Not greasy&quot; is 10 How much did treating your skin disrupt your daily routine? &quot;Very disturbing&quot; is 1 and &quot;Not disturbing&quot; is 10</description>
          <population>The analysis population is defined as those patients from the PP population that have used study medication within 7 days prior to the day of assessment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="295"/>
                <count group_id="O2" value="275"/>
                <count group_id="O3" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" spread="6.6"/>
                    <measurement group_id="O2" value="37.8" spread="7.6"/>
                    <measurement group_id="O3" value="37.2" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected/assessed during the screening period (up to 4 weeks) and during the 8 weeks treatment period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MC2-01 Cream</title>
          <description>MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream. One application daily for 8 weeks
MC2-01 cream: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream</description>
        </group>
        <group group_id="E2">
          <title>CAL/BDP Combination</title>
          <description>CAL/BDP (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%). One application daily for 8 weeks.
CAL/BDP combination: calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%</description>
        </group>
        <group group_id="E3">
          <title>Vehicle</title>
          <description>One application daily for 8 weeks.
Vehicle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="342"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="337"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical Vertebral Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Cervix Carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="115"/>
              </event>
              <event>
                <sub_title>Application site cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="337"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="342"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="337"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="115"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less or equal to 60 days from the time submitted to the sponsor for review. At the end of the Review Period, the sponsor may reasonably require that publication be delayed to permit the filing of patent application. Publication shall not be delayed more than 90 days after receipt of the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Birgitte Vestbjerg</name_or_title>
      <organization>MC2 Therapeutics</organization>
      <phone>+45 2077 2575</phone>
      <email>bve@mc2therapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

